Castrate-Sensitive Prostate Cancer market size is projected to grow at a CAGR of 10% to reach USD 11,753 million by 2034

• The Castrate-Sensitive Prostate Cancer (CSPC) market size in the seven major markets (7MM) was valued at USD 5,143 million in 2025 and is projected to grow at a CAGR of 10%, reaching around USD 11,753 million by 2034. In 2024, the total market size for CSPC therapies in the United States was USD 415 million, with an expected increase over the study period (2024–2034). DelveInsight’s in-depth market research offers essential insights into these trends, helping stakeholders identify growth drivers, emerging opportunities, and potential challenges within the CSPC landscape.
• In 2024, the total number of CSPC cases in the 7MM was estimated at 763,077 and is projected to increase throughout the study period (2024–2034). Additionally, the total prevalent cases of CSPC in the 7MM were reported as 935,398 in 2025, with further growth expected over the forecast period.

DelveInsight’s report “Castrate-Sensitive Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Castrate-Sensitive Prostate Cancer landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

To Know in detail about the Castrate-Sensitive Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Castrate-Sensitive Prostate Cancer Market Forecast

Some of the key facts of the Castrate-Sensitive Prostate Cancer Market Report:

• Key Castrate-Sensitive Prostate Cancer Companies: Janssen Research & Development, Pfizer, AstellasPharma, Bristol-Myers Squibb, Promontory Therapeutics, Hinova, Arcus Biosciences, Inc., AB Science, Suzhou Kintor Pharma, Tracon Pharma, Bayer, AstraZeneca, Clarity Pharma, Novartis, Endocyte, EMD Serono, Medivation, Inc., POINT Biopharma, and others
• Key Castrate-Sensitive Prostate Cancer Therapies: Niraparib, Talzenna, Opdivo (nivolumab), Talazoparib, PT-112, HC-1119, Etrumadenant, Masitinib, GT0918, TRC253, Radium-223 dichloride, AZD4635, 64Cu-SAR-bisPSMA, 68Ga-PSMA-11, 177Lu-PSMA-617, EMD 525797, Darolutamide, Enzalutamide, [Lu-177]-PNT2002, and others
• The Castrate-Sensitive Prostate Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Castrate-Sensitive Prostate Cancer pipeline products will significantly revolutionize the Castrate-Sensitive Prostate Cancer market dynamics.

Castrate-Sensitive Prostate Cancer Overview

CRPC that has spread to other organs has a bad prognosis and a shorter survival time. In comparison to men with localised prostate cancer, who have a 100% 5-year survival rate, men with metastatic prostate cancer have an estimated 5-year survival rate of roughly 30%.
 
Get a Free sample for the Castrate-Sensitive Prostate Cancer Market Report:

https://www.delveinsight.com/report-store/castrate-sensitive-prostate-cancer-market

Castrate-Sensitive Prostate Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Castrate-Sensitive Prostate Cancer Epidemiology Segmentation:

The Castrate-Sensitive Prostate Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalent Cases of Prostate Cancer
• Total Diagnosed Cases of Prostate Cancer
• Age-specific Cases of Prostate Cancer
• Total Diagnosed Cases of Prostate Cancer by Clinical Stages
• Total Non-metastatic and Metastatic Cases of CSPC
• Total Treated Cases of Non-metastatic and Metastatic CSPC] scenario of CSPC

Download the report to understand which factors are driving Castrate-Sensitive Prostate Cancer epidemiology trends @ Castrate-Sensitive Prostate Cancer Epidemiology Forecast

Recent Developments In The Castrate-Sensitive Prostate Cancer Treatment Landscape:

• In September 2025, Jyong Biotech Ltd. (Nasdaq: MENS), a Taiwan-based, science-driven biotechnology company dedicated to developing and commercializing innovative plant-derived drugs, primarily targeting urinary system diseases with initial focus on the U.S., EU, and Asian markets, announced the completion of patient enrollment in its Phase II clinical trial of MCS‑8, an investigational therapy for prostate cancer prevention (PCP). Since the trial’s initiation, over 700 high-risk subjects have been enrolled, marking a significant milestone in the company’s clinical development program.
• In February 2025, Alda Therapeutics, a clinical-stage biotech company advancing a new class of cancer treatments known as RIPTAC™ (Regulated Induced Proximity Targeting Chimeras) therapeutics, has announced that the first patient has been dosed in its Phase 1/2 first-in-human clinical trial (NCT06800313). The study will assess the safety and tolerability of HLD-0915 for patients with metastatic castration-resistant prostate cancer (Castrate-Sensitive Prostate Cancer).

Castrate-Sensitive Prostate Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Castrate-Sensitive Prostate Cancer market or expected to get launched during the study period. The analysis covers Castrate-Sensitive Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Castrate-Sensitive Prostate Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Castrate-Sensitive Prostate Cancer Therapies and Key Companies

• Niraparib: Janssen Research & Development
• Talzenna: Pfizer/AstellasPharma
• Opdivo (nivolumab): Bristol-Myers Squibb
• Talazoparib: Pfizer
• PT-112: Promontory Therapeutics
• HC-1119: Hinova
• Etrumadenant: Arcus Biosciences, Inc.
• Masitinib: AB Science
• GT0918: Suzhou Kintor Pharma
• TRC253: Tracon Pharma
• Radium-223 dichloride: Bayer
• AZD4635: AstraZeneca
• 64Cu-SAR-bisPSMA: Clarity Pharma
• 68Ga-PSMA-11: Novartis
• 177Lu-PSMA-617: Endocyte
• EMD 525797: EMD Serono
• Darolutamide: Bayer
• Enzalutamide: Medivation, Inc.
• [Lu-177]-PNT2002: POINT Biopharma

Discover more about therapies set to grab major Castrate-Sensitive Prostate Cancer market share @ Castrate-Sensitive Prostate Cancer Treatment Market

Castrate-Sensitive Prostate Cancer Market Strengths

• The development of therapies targeting specific mutations are expected to perform better in the upcoming future (e.g.PARP inhibitors).
• Companies are now attempting to enter the first-line setting, particularly Taxane-naive settings, to reduce the need for chemotherapy in patients with Castrate-Sensitive Prostate Cancer

Castrate-Sensitive Prostate Cancer Market Opportunities

• Uptake of potential emerging therapies with better clinical profile, specially targeting the mutations like PARP inhibitors (i.e., BRCA mutation) expected to be fast.
• Rising prevalence of prostate cancer due to rapidly aging population and growing awareness among people will provide the larger window of opportunity for new treatment.

Scope of the Castrate-Sensitive Prostate Cancer Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Castrate-Sensitive Prostate Cancer Companies: Janssen Research & Development, Pfizer, AstellasPharma, Bristol-Myers Squibb, Promontory Therapeutics, Hinova, Arcus Biosciences, Inc., AB Science, Suzhou Kintor Pharma, Tracon Pharma, Bayer, AstraZeneca, Clarity Pharma, Novartis, Endocyte, EMD Serono, Medivation, Inc., POINT Biopharma, and others
• Key Castrate-Sensitive Prostate Cancer Therapies: Niraparib, Talzenna, Opdivo (nivolumab), Talazoparib, PT-112, HC-1119, Etrumadenant, Masitinib, GT0918, TRC253, Radium-223 dichloride, AZD4635, 64Cu-SAR-bisPSMA, 68Ga-PSMA-11, 177Lu-PSMA-617, EMD 525797, Darolutamide, Enzalutamide, [Lu-177]-PNT2002, and others
• Castrate-Sensitive Prostate Cancer Therapeutic Assessment: Castrate-Sensitive Prostate Cancer current marketed and Castrate-Sensitive Prostate Cancer emerging therapies
• Castrate-Sensitive Prostate Cancer Market Dynamics: Castrate-Sensitive Prostate Cancer market drivers and Castrate-Sensitive Prostate Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Castrate-Sensitive Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Castrate-Sensitive Prostate Cancer Market Access and Reimbursement 

To know more about Castrate-Sensitive Prostate Cancer companies working in the treatment market, visit @ Castrate-Sensitive Prostate Cancer Clinical Trials and Therapeutic Assessment